Filing Flows › Personalis (PSNL) › Guidance & outlook
Personalis (PSNL) guidance and outlook
Personalis' 10-Q filed Nov 4, 2026 makes 16 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 4, 2026
- We expect variability in our gross margins over the medium-term due to fluctuations in customer mix and volume, investments in newer sequencing platforms and new capabilities, such as automation of laboratory workflows, and processing of diagnostic tests for the clinical market while we work to secure reimbursement.
- Over the long-term, we anticipate gross margin expansion as we expect increases in revenue to result in economies of scale.
- We expect research and development expenses to continue to increase over time to support the growth of our clinical diagnostic offerings.
- We expect selling, general and administrative expenses to continue to increase over time to support the growth of our clinical diagnostic offerings.
- We expect variability in revenue from pharmaceutical companies in the future due to the timing of their patient enrollment for clinical trials or project schedules.
- The decrease in revenue from enterprise sales in the third quarter of 2026 and the first nine months of 2026 compared to the same periods of 2025 was due to the expected decrease in the number of samples processed for Natera after the second quarter of 2025 when the minimum volume commitments in our agreement with Natera expired.
- We no longer have a commercial relationship with Natera and do not expect to have one going forward .
- We have based these future funding requirements on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.
- We plan to fund our material cash requirements with our existing cash and cash equivalents and short-term investments, which amounted to $190.6 million as of September 30, 2026, as well as anticipated cash receipts from customers.
- However, we generally do not have binding and enforceable purchase orders beyond the short term, and the timing and magnitude of purchase orders beyond such period is difficult to accurately project.
- We currently expect spending in this area to increase compared to the levels in 2025 in order to support expected higher levels of revenue.
- Our primary use of cash relates to employee compensation, spend on professional services, spend related to research and development projects, and other costs to support our research and development and selling, general and administrative functions.
Personalis' latest quarter
Personalis, Q3 2026: revenue $25.6M (+77% year over year), operating margin -138.8%, net loss $33.8M, operating cash flow −$27.1M. The chart follows the revenue to costs, profit and cash.
Questions
What does Personalis expect?
We expect variability in our gross margins over the medium-term due to fluctuations in customer mix and volume, investments in newer sequencing platforms and new capabilities, such as automation of laboratory workflows, and processing of diagnostic tests for the clinical market while we work to secure reimbursement. Over the long-term, we anticipate gross margin expansion as we expect increases in revenue to result in economies of scale. We expect research and development expenses to continue to increase over time to support the growth of our clinical diagnostic offerings.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.